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1. Introduction
  
 The mosquito-borne dengue virus (DENV) is a 
single positive-stranded RNA of Flavivirus, known 
to instigate dengue fever (DF). This infection is 
commonly propagated by the vector, Aedes mosquito, 
including A. aegypti and A. albopictus. In addition, the 
primary infection is typically asymptomatic, while the 
secondary is characterized by symptom progression, 
comprising high fever. Moreover, subsequent 
stages commonly feature dengue hemorrhagic 
fever (DHF), which is implicated in plasma leakage, 
where further outflow into the interstitial spaces 
have been associated with dengue shock syndrome 
(DSS). This phenomenon is known to be involved 
with cardiovascular compromise, and further shock 
(Bäck and Lundkvist 2013). In addition, a total of five 
serotypes have been identified to date, including 
the DENV-1, DENV-2, DENV-3, DENV-4 and DENV-5 
(Mustafa et al. 2015). 
 The dengue cases reported worldwide exceeds 
double with every passing decade between 1990 
at 8.3 million (3.3–17.2 million), and 2013, at 58.4 
million (23.6–121.9 million) (Stanaway et al., 2016). 
Moreover, one of the most significant global burden is 
recorded in Indonesia (Nadjib et al. 2019). Harapan et 
al. (2019) showed an elevating trend over the course 
of 50 years, where the incidence rates appears cyclic, 
and peaking at every 6-8 years The DENV is highly 
prevalent amongst the pediatric urban population 
(Prayitno et al. 2017), and DENV-2 is identified as the 
most popular serotype (Sasmono et al. 2018).
 A total of three structural proteins are contained 
in the DENV RNA genome, including the precursor 
membrane (prM), capsid (C), and envelope (E). 
Specifically, E protein comprises a transmembrane 
region as well as an ectodomain, sub-divided further 
into 3 domains. These include envelope domain I 
(EDI), which is responsible for structure organization, 
II (EDII), known to be a highly conserved fusion 
loop, and III (EDIII), involved in receptor binding 
(Khetarpal and Khanna, 2016). Furthermore, these 
molecules are estimated to be vital components in 
vaccine development, and also as a crucial target for 
antibiotics inhibition and neutralization (Chiang et 
al. 2013; Clark et al. 2016).
 Moreover, various vector control strategies are 
considered during the dengue prevention process. 
This is achievable at the larval breeding sites, 
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through some management approaches, including 
via biological, chemical, and environmental means. 
These often present with several limitations, 
especially in the aspect of sustainability (long-term) 
and efficiency. Previous studies showed reduced 
vector competence, following the introduction of 
Wolbachia to a population of A. aegypti, although long 
or shorter trial period is required to attain success 
at numerous sites, which is insufficient in settings 
characterized by high transmission. Therefore, 
vaccine use is considered to be most ideal (Dorigatti 
et al. 2018).
 There is significant focus on remedies against 
E-protein during the vaccine development process. 
This molecule implicated in viral entry and binding, 
as well as structural integrity. Despite the increased 
need to evaluate safer techniques, E-protein site is 
considered to be a viable target (Fahimi et al. 2018). 
Aguiar et al. (2016) reported on the several health 
risks of Dengvaxia (CYD-TDV), which is the first ever 
approved dengue vaccine–, in terms of increased 
primary infection potential. Chakraborty et al. (2010) 
highlighted high E-protein variability as a major 
challenge, hence the need for an in silico approach in 
predicting the epitope and human leukocyte antigen 
(HLA) candidates. 
 Sette and Fikes (2003) acknowledged epitope-
based design as a valuable approach focused on 
immune response, particularly in terms of increased 
safety and potency. A study by Soria-Guerra et 
al. 2015) showed antigens to be characterized 
by epitopes, with the capacity to ensure specific 
stimulation. In addition, numerous studies have 
shown the tendency for epitope-based vaccines to 
efficiently elicit immune responses against a number 
of pathogens (Liu et al. 2006, 2017; Huang et al. 
2013). Hence, the predictions attained with the use 
of in silico tools during vaccine design is expected to 
provide substantial advantages in contrast with some 
conventional methods, particularly in the aspect of 
lower costs and faster output.
 The aim of this study, therefore, is to use various 
in silico tools in the design of peptide vaccines 
based on epitope (T-cell and B-cell types), using the 
available envelope glycoprotein sequences of DENV-
2. The results generated are expected to confirm the 
recommendation of new candidates.
 
2. Materials and Methods
 Figure 1 shows the study method adapted from 
Dash et al. (2017), with some modifications.
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2.1. Protein Sequence Retrieval, Evaluation 
Analysis and Antigenic Protein Evaluation
Furthermore, the UniProt database served as 
a source for all the available sequences in the E of 
DENV-2 (Rolf et al. 2017). This was followed by the 
use of ClustalW tool for multiple sequence alignment. 
Therefore, the MEGA X software was used to assemble 
the phylogenetic tree (Kumar et al. 2018), which was 
generated in the nwk format with the iTOL web server 
(Letunic and Bork 2019). Subsequently, most efficient 
antigenic protein from the sequences available was 
predicted with VaxiJen v2.0 (Doytchinova and Flower 
2007).
2.2. T-Cell Epitope Identification and 
Conservancy Analysis
The NetCTL 1.2 server was used to identify T-cell 
epitope at setting values of 0.05, 0.1, and 0.5 for weight 
on TAP transport efficiency, weight on C terminal 
cleavage and epitope identification threshold, 
respectively. The limits for sensitivity and specificity 
0.89 and 0.94, respectively  (Larsen et al. 2007). In 
addition, immune epitope database (IEDB) tools 
were used to predict the conservancy and processing 
(Tenzer et al. 2005; Sidney et al. 2007), to ensure the 
candidates are forecasted based on peptide processing 
within the cell. Moreover, the proteasomal cleavage/
TAP transport/MHC class I in this study was used as a 
merged predictor tool to predict the overall score for 
each (Tenzer et al. 2005), by adopting the stabilized 
matrix method (Peters and Sette 2005). The T-cell 
identification process was restricted to 12 human 
leukocyte antigen (HLA) supertypes, and all alleles 
were evaluated prior to the prediction process, with 
peptide lengths set at 9.0.
2.3. Prediction of Population Coverage and 
Allergenicity Assessment
The predictions for epitopes was performed using 
the IEDB population coverage tool (Bui et al. 2006). 
This involved selecting the combined MHC-I and 
MHC-II alleles obtained from the population datasets. 
Subsequently, those collected from Northeast, East, 
South, Southwest, and Southeast Asia, Europe, West, 
East, Central, North, and South Africa, South, North, 
and Central America, Oceania, as well as West Indies 
were predicted.
Therefore, AllergenFP 1.0. was used to analyze the 
allergenicity of a predicted epitope. This involved 
applying a concept based on the respective descriptor 
fingerprints, and was further implemented into a 
four step algorithm. Furthermore, this was required 
to identify the probable non-allergens and allergens 
(Dimitrov et al. 2014).
2.4. Molecular Simulation Analysis of HLA-
Allele Interaction
The PEP-FOLD3 web-based server was used 
to present all five predicted epitopes in three-
dimensional (3D) structures (Lamiable et al. 2016), 
and the five best clusters were represented for each 
sequence. Therefore, structures characterized by the 
least energy model were selected for further analysis.
In addition, the SWISS-MODEL online tool was 
used to generate a hypothetical 3D structure of 
HLA-C*12:03 with the homology modelling (Biasini 
et al. 2014). The hypothetical structure was then 
minimized and corrected using a ModRefiner (Xu 
and Zhang 2011), before validating with Verify 3D 
(Eisenberg et al. 1997), PROCHECK (Laskowski et al. 
1993), ERRAT (Colovos and Yeates 1993), and QMEAN 
(Benkert et al. 2008).
The AutoDock Vina was used for molecular 
docking analysis (Trott and Olson 2009) in PyRx 0.8. 
Therefore, MGLTools 1.5.6 was adopted in the addition 
of AutoDock atom types and Gasteiger charges to the 
structure, after introducing the hydrogen atoms. The 
output file was presented in a pdbqt format, and used 
as a docking target. In addition, the exhaustiveness 
was set at 8, and the center coordinates were 
customized at X:16.8453, Y:-42.3440, and Z:3.6168, in 
accordance with a default, while the space searched 
was consequently optimized to 57.0680 Å x 70.7331 
Å x 60.8774 Å prior to docking.
2.5. Identification of the B-cell Epitope
The B-cell epitope candidate was predicted using 
various IEDB tools, and the following evaluations 
where performed: prediction for antigenicity 
(Kolaskar and Tongaonkar 1990), Chou and Fasman 
β-turn (Chou and Fasman 1977), Emini surface 
accessibility (Emini et al. 1985), Bepipred linear 
epitope based on Hidden Markov model (Larsen et 
al. 2006), and Karplus and Schulz flexibility (Karplus 
and Schulz 1985).
3. Results
 The epitopes with potential against DENV-2 
were predicted using several in silico tools, through 
methods adapted from Dash et al. (2017) with 
modifications in terms of the tools and target used.
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3.1. Evolutionary Analysis and Antigenicity 
Prediction of the E Sequences
A total of 232 E protein sequences derived from 
dissimilar DENV-2 variants were obtained from 
the UniProtKB database. Therefore, MEGA X was 
used to perform multiple sequence analysis before 
calculating the overall mean distance. Furthermore, 
bootstrap and unweighted group method with 
arithmetic mean (UPGMA) was used to construct 
the phylogenetic tree with 1,000 replications. 
The parameters of gamma distribution were set 
to 1, before removing all ambiguous positions for 
each sequence pair. Figure 2 shows the phylogram 
generated using the nwk format obtained from the 
assembled tree, with the aid of an iTOL web server. 
The results indicate the existence of closely related 
protein sequences, and was supported by the value 
for overall mean distance (0.02).
 
Figure 2. Evolutionary divergence analysis of the 232 envelope glycoprotein sequences of DENV-2 available, results 
displayed in a phylogenetic tree. Bootstrap value of branches corresponding to partitions reproduced in less 
than 0.50 of bootstrap replicates (1,000 replicates) were not shown
Therefore, the VaxiJen v2.0 web-based server 
was subsequently used to analyze the sequences 
for antigenicity, and the predictions  were 70-
89% accurate with auto cross covariance (ACC). 
Furthermore, the most antigenic protein was 
determined to be UniprotKB id: B4XPM1, with a 
prediction score of 0.6947. Hence, this sequence was 
selected for applications in further analysis.
3.2. T-cell Epitope Identification and 
Conservancy Analysis
 The NetCTL 1.2 server was used to predict the five 
most potent epitope on the basis of the combinatorial 
score, as shown in Table 1. In addition, numerous 
epitopes were analyzed without compromising 
specificity or sensitivity, with a threshold of 0.5. The 
predictions were also based on potency in cellular 
peptide processing and conservancy, through the 
respective antigens. This was performed by using 
various IEDB tools to respectively generate a total 
score and conservancy percentage.
 The proteasomal cleavage/TAP transport/MHC 
class I combined predictor tool was used to analyze 
the binding and interactions between MHC-I 
alleles and the 9-mer T-cell epitopes identified. 
The binding capacity of peptides with IC50 value 
<50 nm are estimated to be strong, with <500 nm 
as intermediate and <5,000 nm was considered 
weak. Hence, the threshold was regulated at <200 
nm during this current investigation, in order 
attain a higher affinity. The results showed an 
interaction between the KAWLVHRQW epitope and 
the predominant MHC-I alleles, despite the high 
conservancy (96.98%) retained across all antigens 
(Table 2). Therefore, KAWLVHRQW was deemed to be 
the epitope candidate based on the aforementioned 
factors. Moreover, HLA-A*68:23 HLA-C*12:03 and 
HLA-B*27:20 reportedly interacted with all five 
epitopes, and were consequently adopted in further 
analysis.
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3.3. Prediction of Population Coverage and 
Allergenicity Assessment
 Some of the essential aspects of epitope-based 
vaccine design include allergenicity and population 
coverage, resulting from considerations attributed 
to the range of affected people, as well as safety 
characteristics of the vaccines. The AllegenFP 1.0 
and IEDB were tools respectively used to predict 
the cumulative percentage of allergenicity and 
population coverage for KAWLVHRQW. Moreover, 
similar assessment was also performed with 
the five epitopes identified in contrast with the 
three HLA alleles. Table 3 showed the presence of 
KAWLVHRQW in all regions analyzed. Meanwhile 
the allergenicity sequence was forecasted to be a 
probable non-allergen, and glycine cleavage system 
protein H (UniprotKB–Q7M1V3) was identified as 
the nearest protein, belonging to the species Oryza 
sativa. The results showed a generally low population 
coverage for all five epitopes compared to the three 
alleles, Table 4 showed a relatively better coverage 
with HLA-C*12:03, and the allele was consequently 
selected for further molecular modelling.  
3.4. Molecular Simulation Analysis of HLA-
Allele Interaction
  The SWISS-MODEL was used to generate a 3D 
hypothetical structure for HLA-C*12:03, based 
on homology modelling using protein sequences 
available in the EBI database (C*12:03:01:01), and 
was subsequently refined with the ModRefiner 2.0. 
In addition, the structures generated were validated 
with Verify3D, PROCHECK, ERRAT, and QMEAN, based 
on the SAVES v5.0 server (https://servicesn.mbi.ucla.
edu/SAVES/). The results showed an average 3D-1D 
score of 0.2 in 94.12% of the residues, with Verify3D 
assessment, and was then considered to be passable. 
Moreover, 84.2697 was determined to be the overall 
score possessed by the model, using the ERRAT 
analysis. This was further categorized as good, because 
the value was above the 80.00 criterion. Based on the 
Ramachandran plot generated with PROCHECK, the 
favoured regions were characterized by 92.5% of the 
residue, with the additional allowed areas measuring 
7.1%, 0.4% for generously allowed, and disallowed was 
0%. Figure 3a shows the presence of over 90% structure 
in a preferred region, hence the model is further 
considered to be of good quality. Figure 3b showed 0.26 
as the QMEAN Z-Score, while the normalized QMEAN4 
was within the range of 0.5 to 1, indicating the model 
Table 1. Five most potent epitopes based on their 
combinatorial score, obtained from NetCTL 1.2 
server
Supertype
A1
B58
B8
B44
A24
ITEAELTGY
KAWLVHRQW
IGKALHQVF
QEGAMHTAL
SYSMCTGKF
2.7293
1.8640
1.7518
1.6721
1.6264
Epitope Combinatorial score (nm)
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Table 2. Interaction, binding and conservancy of the identified T-cell epitope
Epitope
IGKALHQVF
ITEAELTGY
KAWLVHRQW
QEGAMHTAL
SYSMCTGKF
HLA-B*15:03
HLA-C*12:03
HLA-B*27:20
HLA-A*02:50
HLA-A*32:07
HLA-A*32:15
HLA-A*68:23
HLA-B*40:13
HLA-C*03:03
HLA-C*07:02
HLA-B*15:02
HLA-A*68:23
HLA-C*12:03
HLA-A*26:02
HLA-B*15:17
HLA-A*32:07
HLA-B*27:20
HLA-C*05:01
HLA-A*32:15
HLA-C*03:03
HLA-B*40:13
HLA-C*14:02
HLA-B*57:01
HLA-B*58:01
HLA-B*40:13
HLA-B*27:20
HLA-B*15:17
HLA-A*02:50
HLA-C*12:03
HLA-A*68:23
HLA-A*32:01
HLA-A*32:15
HLA-A*32:07
HLA-C*03:03
HLA-B*27:20
HLA-A*68:23
HLA-B*40:01
HLA-A*02:50
HLA-C*12:03
HLA-B*40:13
HLA-A*32:07
HLA-B*15:02
HLA-A*32:15
HLA-A*24:03
HLA-A*32:07
HLA-C*14:02
HLA-B*27:20
HLA-A*68:23
HLA-A*32:15
HLA-B*40:13
HLA-C*07:02
HLA-C*12:03
HLA-A*24:02
HLA-A*23:01
13.20
16.60
25.90
57.60
71.60
72.80
95.70
101.60
124.60
160.80
186.30
3.00
21.30
26.60
30.50
32.90
76.60
77.00
83.20
93.50
154.50
186.00
3.90
7.30
9.80
12.30
17.80
18.80
19.90
20.30
52.40
73.80
80.90
18.60
18.90
46.50
52.80
53.90
71.50
92.90
127.40
172.30
198.30
4.60
4.80
17.60
18.30
32.30
57.80
60.00
62.00
81.30
156.50
157.90
94.40
96.98
96.98
96.98
96.98
1.39
1.30
1.10
0.76
0.66
0.65
0.54
0.51
0.42
0.31
0.25
1.99
1.14
1.04
0.99
0.95
0.59
0.58
0.55
0.50
0.28
0.20
1.40
1.13
1.01
0.91
0.75
0.72
0.70
0.69
0.28
0.13
0.09
0.48
0.47
0.08
0.03
0.02
-0.11
-0.22
-0.36
-0.49
-0.55
1.69
1.67
1.10
1.09
0.84
0.59
0.57
0.56
0.44
0.16
0.15
MHC-I Allele IC50 (nm) Epitope 
conservancy (%)
Total score (proteasomal cleavage, TAP 
Transport, MHC-I score, processing score)
as acceptable for use in subsequent analysis. The 
results of molecular docking higher binding affinity of 
KAWLVHRQW and ITEAELTGY against HLA-C*12:03 at 
-7.5 kcal/mol and -7.6 kcal/mol, respectively, as shown 
in Table 5. These outputs indicate a higher binding 
probability with both epitopes, and the consequent 
capacity to initiate immune response.
 The potent B-cell epitope was identified by 
evaluating the protein sequence previously selected 
from screening with VaxiJen v2.0. Subsequently, the 
sequence potency, based on the peptide position were 
predicted using various IEDB tools.
 The protein sequence antigenicity was evaluated 
using a method by Kolaskar and Tongaonkar. This 
technique emphasizes on the occurrence frequency 
and the physicochemical properties of the amino acid 
components, and is performed on the experimentally 
known epitopes. In addition, high antigenicity is 
indicated by values >1.00. The results showed that the 
average, minimum and maximum scores are 1.024, 
0.861, and 1.272 respectively. Table 6 and Figure 4a 
show a total of 22 epitopes, which reportedly satisfied 
the threshold requirement, and further indicates the 
tendency to express a B-cell response.
 The protein was evaluated for emini surface 
accessibility, being one of the characteristics of a 
potent B-cell epitope. Table 7 and Figure 4b showed 
the high accessibility of the region between 77-88 and 
358-363. The β-turn prediction by Chou and Fasman 
showed regions of 65-90, 97-113, and 217-232 to be 
highly hydrophilic, as observed in Figure 4c. Figure 4d 
showed the prediction for increased flexibility within 
the region of 61-92, 141-177, and 220-240, based on 
Karplus and Schulz. In addition, prediction for β-turn 
by Chou and Fasman, and flexibility by Karplus and 
Schulz were estimated based on the relationship 
between β-turn potential, flexibility and hydrophilicity 
with antigenicity. Moreover, a total of nine epitopes 
were determined to be the potent B-cell type, using 
the bepipred linear prediction, as shown in Table 8 
and Figure 4e. Based on the potential use of E protein 
against DENV-2 the results suggest the predicted 
peptide sequences between the position range of 77 
to 85 as potent B-cell epitopes, for possible application 
in vaccine design.
4. Discussion
 Several approaches are involved in dengue vaccine 
development, including the inactivated forms, 
tetravalent live attenuated types, plasmid DNA, 
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Table 3. Population coverage of the proposed epitope 
against DENV-2. aProjected population 
coverage, baverage number of epitope 
hits/HLA combinations recognized by the 
population, cminimum number of epitope hits/
HLA combinations recognized by 90% of the 
population
Population/area
Central Africa
Central America
East Africa
East Asia
Europe
North Africa
North America
Northeast Asia
Oceania
South Africa
South America
South Asia
Southeast Asia
Southwest Asia
West Africa
West Indies
Average
Standard 
deviation
Coveragea
(%)
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
100.00
0.00
15.04
6.82
16.45
16.66
19.99
13.4
19.98
16.35
14.62
6.7
17.61
18.12
14.76
14.97
15.42
9.29
14.76
3.9
14.24
6.07
15.47
15.41
18.64
12.85
18.77
15.39
13.68
6.13
16.45
17.13
14.02
14.19
14.27
8.63
13.83
3.72
Average_Hitb Pc90c
Class combined
Population/area
Central Africa
East Africa
East Asia
Europe
North Africa
North America
Northeast Asia
Oceania
South Africa
South America
South Asia
Southeast Asia
Southwest Asia
West Africa
Average
Standard 
Deviation
Coveragea
(%)
5.33
2.24
0.41
14.75
10.54
5.73
4.71
4.47
1.99
4.55
10.32
1.48
8.26
3.45
5.59
3.91
0.27
0.11
0.02
0.74
0.53
0.29
0.24
0.22
0.1
0.23
0.52
0.07
0.41
0.17
0.28
0.2
0.53
0.51
0.5
0.59
0.56
0.53
0.52
0.52
0.51
0.52
0.56
0.51
0.55
0.52
0.53
0.02
Average_Hitb Pc90c
Class combined
Table 4. Population coverage of the identified five epitopes 
against HLA-C*12:03. aProjected population 
coverage, baverage number of epitope hits/HLA 
combinations recognized by the population, 
cminimum number of epitope hits/HLA 
combinations recognized by 90% of the population
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Table 5. Molecular docking of the identified epitopes 
against HLA-C*12:03
Table 6. Prediction of antigenic region of protein using 
Kolaskar and Tongaonkar antigenicity method
Ligand Start End
IGKALQHF
KAWLVHRQW
QEGAMHTAL
SYSMCTGKF
ITEAELTGY
20
42
53
71
88
113
128
137
161
194
205
234
247
275
290
305
318
331
344
374
425
456
33
48
63
77
95
120
133
143
170
200
222
241
255
288
297
312
327
339
359
391
451
465
-7.0
-7.5
-6.5
-6.9
-7.6
WVDIVLEHGSCVTT
DFELIKT
PATLRKYCIEA
ASRCPTQ
KRFVCKHS
IVTCAMFT
KIVQPE
YTIVITP
EIKVTPQSSI
NEMVLLQ
AWLVHRQWFLDLPLPWLP
KETLVTFK
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GNLLFTGHLKCRLR
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GTIVIRVQYE
SPCKIPFEI
KRHVLGRLITVNPIVT
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Figure 4. B-cell epitope prediction using various IEDB tools. (a) Kolaskar and Tongaonkar antigenicity prediction, (b) 
Emini surface accessibility prediction, (c) chou and Fasman β-turn prediction, (d) karplus and Schulz flexibility 
prediction, and (e) Bepipred linear epitope prediction
virus-like particles, virus-vectored, and recombinant 
subunit vaccines. Fahimi et al. (2018); Tripathi and 
Shrivastava (2018) highlighted E protein as one 
of the principal focus during development, based 
on the variety of functions in DENV. This molecule 
is estimated to play a significant role as a receptor 
attachment site to ensure cellular viral entry, and 
also represents an appropriate target during the 
development of vaccine (De Paula et al. 2008; Quinan 
et al. 2016; Versiani et al. 2017; Shukla et al. 2018). 
Therefore, similarity was evaluated by performing the 
multiple sequence alignment on the 232 E sequences 
of DENV-2 available. The results showed significant 
similarity, with the tendency to provide strong cross-
reactivity against various DENV-2 strains (Dash et al. 
2017). 
 Tahir Ul Qamar et al. (2019) acknowledged the 
identification of desired sequences as a major 
challenge during epitope-based vaccine development, 
especially with samples capable of high antigenicity. 
Therefore, VaxiJen 2.0, was adopted as a robust 
in predicting the antigenicity of all 232 E DENV-2 
sequences. This analysis is based on the sample’s auto 
cross covariance (ACC) transformation to uniform 
vectors with fundamental amino acid characteristics 
(Doytchinova and Flower 2007). The result showed 
the highest antigenicity in sequence B4XPM1, which 
was then subjected to further analysis.
 The cognate antigen referred to as epitopes 
are fractions of the B- and T- cells implicated as 
mediators in adaptive immunity. Also, both forms 
ought to be contained in an ideal peptide vaccine, 
hence epitope identification is crucial for the 
development of optimized products (Sette and Fikes 
2003). Specifically, the T-cell form is identified by 
analyzing the E sequence with NetCTL 1.2, which is 
reliable in predicting cytotoxic T-lymphocyte (CTL) 
9-mer epitopes. This tool practically integrates the 
predictions of proteasomal cleavage, and the MHC 
class I affinity and TAP transport efficiency for 12 
known supertypes (Larsen et al. 2007). The five 
candidates with most significant combinatorial 
scores were further analyzed with numerous 
immunoinformatics tools selected from the Immune 
Epitope Database (IEDB). These include conservancy 
analysis and proteasomal cleavage/TAP transport/
MHC class I combined predictor tool. The results 
demonstrate the greatest number of human 
leukocyte antigen (HLA) alleles bonds with epitope 
KAWLVHRQW. This indicates the encouragement of 
promiscuity following the increasing coverage. Based 
on this method, proper interaction was established 
between all five candidates and a total of three HLA 
alleles, encompassing HLA-A*68:23 HLA-B*27:20 and 
HLA-C*12:03 (Tian et al. 2018). Also, high conservancy 
was observed across the 232 E sequences. Hence, 
further population coverage analysis were conducted 
on the epitope, alongside all three HLA alleles.
 The broad population coverage is ensured by 
considering the promiscuity factor during the 
epitope selection process. This results generated 
based on the discrepancies in allele expression 
frequency with different populations show the 
individual reaction to different peptide sets obtained 
from a specific pathogen. In addition, the design 
also needs to evaluate the individual constituent 
allergenicity, as administration possibly results in 
adverse reactions (Kelso et al. 1999). The population 
coverage of the proposed epitope KAWLVHRQW 
against MHC-I and MHC-II alleles was then analyzed, 
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Table 7. Prediction of Emini surface accessibility of the 
protein
Start End
34
48
64
77
121
130
154
162
231
240
288
324
358
390
404
41
57
70
88
126
135
160
169
236
248
293
329
363
395
410
MAKNKPTL
TEAKHPATLR
KLTNTTT
QGEPSLNEEQDK
CKKNME
VQPENL
DTGKHGK
IKVTPQSS
WIQKET
FKNPHAKKQ
RMDKLQ
VQYEGD
VTEKDN
SWFKKG
TTMRGAK
8
10
7
12
6
6
7
8
6
9
6
6
6
6
7
Peptide Length
Start End
51
70
144
168
223
245
327
359
362
51
85
158
170
229
246
332
360
374
K
TASRCPTQGEPSLNEE
HSGEENAVGNDTGKH
SSI
GADTQGS
AK
EGDGSP
TE
DNPVNIEAEPPFG
1
16
15
3
7
2
6
2
13
Peptide Length
Table 8. Prediction of Bepipred linear epitopes of the 
protein
and also for allergenicity using AllergenFP 1.0. 
Hence, this tool provides a balanced prediction for 
both non-allergens and allergens (Dimitrov et al. 
2014). Moreover, the population coverage of all five 
epitope candidates were evaluated against the three 
HLA alleles, and KAWLVHRQW was determined 
to demonstrate highest coverage globally. The 
allergenicity prediction further showed the epitope 
as a probable non-allergen, where O. sativa, which 
is majorly used as food with several medicinal 
and health benefits, due to the significantly close 
protein characteristics. According to Jamil and Anwar 
(2016), the use is considered to be generally safe. 
in addition, the HLA-C*12:03 allele demonstrated 
greater coverage in contrast with the others, and was 
subsequently used for molecular simulation analysis 
(Oyarzun and Kobe 2015). 
 The SWISS-MODEL was used to generate a 
hypothetical three-dimensional (3D) structure for 
the allele HLA-C*12:03,  according to the homology 
modelling (Biasini et al. 2014). This development 
was based on the protein sequences available at 
the EBI database (C*12:03:01:01) (Rodriguez-Tomé 
et al. 1996). In addition, the ModRefiner was used 
for structural optimization, by constructing and 
refining the structure from Cα traces, by minimizing 
the atomic-level energy through a two-step 
process (Xu and Zhang 2011). Subsequently, several 
tools were used to validate the hypothetical 3D 
structure, including the ERRAT (Colovos and Yeates 
1993), Verify3D (Eisenberg et al. 1997), QMEAN 
(Benkert et al. 2008) and PROCHECK (Laskowski 
et al. 1993). Particularly, the approached used to 
measure correctness through Verify3D was based 
on compatibility with the amino acid present. 
Furthermore, the overall score observed was over 
80.00, and further indicates a good model (Eisenberg 
et al. 1997). The protein model quality was measured 
with PROCHECK by exhaustively evaluating the 
stereochemistry. Therefore, the residues present at 
the most allowed and favorable regions had a score 
>90%, and the model was further considered to be of 
high-quality (Laskowski et al. 1993). The ERRAT was 
used to measure correctness level of specific protein 
structure regions. This determination was based 
on the nature of the noncovalent pairwise bonded 
interactions (CO, CN, CC, NN, OO, and NO). The model 
was considered as good with score >80.00 (Colovos 
and Yeates 1993). Furthermore, QMEAN was used for 
the composite scoring function, due to the proteins’ 
varied geometrical aspects (Benkert et al. 2011). 
The results collectively suggest the acceptability 
of HLA-C*12:03 as a the proposed hypothetical 
structure to be adopted during molecular docking 
simulations.
 The bond between immunogenic peptides 
and MHC receptors is essential for peptide 
immunogenicity mechanisms. The binding affinity 
between epitopes and HLA alleles was analyzed using 
molecular docking, performed by acknowledging 
the receptor capacity of HLA molecules, where 
epitopes serve as candidate ligand (Dash et al. 
2017). These findings indicate the higher probability 
for KAWLVHRQW and ITEAELTGY to bind with 
HLA-C*12:03, and consequently trigger an immune 
response.
 The B-cell epitopes are considered an essential 
component in epitope-based vaccine development, 
due to the mediation role played during viral 
neutralization in potent humoral immune response 
(Sette and Fikes 2003). The candidate epitope was 
predicted from the B4XPM1 sequence evaluated, 
using the numerous immunoinformatics tools 
present in IEDB. This activity was performed through 
antigenicity assessment, based on the considerations 
of surface accessibility, amino acid constituents, 
β-turn potential, polarity and flexibility (Chou and 
Fasman 1977; Karplus and Schulz 1985; Emini et al. 
1985; Larsen et al. 2006; Kolaskar and Tongaonkar 
1990). Collectively, the results indicate a need to 
consider the peptide region ranging from position 77 
to 85 as potent B-cell epitope.
 Moreover, in silico methods have significantly 
influenced epitope-based dengue vaccine 
development. The time and cost required for during 
the identification process is reduced significantly. 
Therefore, candidates for vaccine development were 
successfully provided against DENV-2 envelope 
glycoprotein. However, Further research is needed 
to improve the design of vaccines required for 
other serotypes, and also to facilitate models for 
multivalent variants.
5. Conclusion
 The results indicate epitope KAWLVHRQW 
obtained from peptide region 77 to 85 at positions 
204-212 to be the most potent B-cell and T-cell. 
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In summary, the developed components were 
estimated to confer a significantly high immunity 
against DENV-2.
References
Adhikari UK et al. 2018. Immunoinformatics approach for 
epitope-based peptide vaccine design and active site 
prediction against polyprotein of emerging oropouche 
virus. Journal of Immunology Research 2018:1-22. DOI: 
10.1155/2018/6718083
Aguiar M et al. 2016. The risks behind Dengvaxia 
recommendation. The Lancet Infectious Diseases 
16:882–883. DOI:10.1016/S1473-3099(16)30168-2
Ayub G et al. 2016. Prediction and conservancy analysis of 
promiscuous T-cell binding epitopes of Ebola v i rus 
L protein: an in silico approach. Asian Pacific Journal 
of Tropical Disease 6:169–173. DOI:10.1016/S2222-
1808(15)61007-6
Bäck TA, Lundkvist Å. 2013. Dengue viruses-an overview. 
Infection Ecology and Epidemiology 3:19839. 
DOI:10.3402/iee.v3i0.19839
Benkert P et al. 2008. QMEAN: a comprehensive scoring 
function for model quality assessment. Proteins: 
Structure, Function and Genetics 71:261–277. 
DOI:10.1002/prot.21715
Benkert P et al. 2011. Toward the estimation of the 
absolute quality of individual protein structure 
models. Bioinformatics 27:343–350. DOI:10.1093/
bioinformatics/btq662
Biasini M et al. 2014. SWISS-MODEL:modelling protein 
tertiary and quaternary structure using evolutionary 
information. Nucleic Acids Research 42:1–7. 
DOI:10.1093/nar/gku340
Bui HH et al. 2006. Predicting population coverage of 
T-cell epitope-based diagnostics and vaccines. BMC 
Bioinformatics 7:153. DOI:10.1186/1471-2105-7-153
Chakraborty S et al. 2010. A computational approach for 
identification of epitopes in dengue virus envelope 
protein: a step towards designing a universal dengue 
vaccine targeting endemic regions. In Silico Biology 
10:235–246. DOI:10.3233/ISB-2010-0435
Chiang CY et al. 2013. Induction of robust immunity by the 
emulsification of recombinant lipidated dengue-1 
envelope protein domain III. Microbes and Infection 
15:719–728. DOI:10.1016/j.micinf.2013.06.002
Chou PY, Fasman GD. 1977. Secondary structural prediction 
of proteins from their amino acid sequence. Trends 
in Biochemical Sciences 2:128–131. DOI:10.1016/0968-
0004(77)90440-6
Clark MJ et al. 2016. GNF-2 inhibits dengue virus by targeting 
abl kinases and the viral E protein. Cell Chemical Biology 
23:443–452. DOI:10.1016/j.chembiol.2016.03.010
Colovos C, Yeates TO. 1993. Verification of protein structures: 
patterns of nonbonded atomic interactions. Protein 
Science 2:1511–1519. DOI:10.1002/pro.5560020916
Dash R et al. 2017. In silico-based vaccine design against 
Ebola virus glycoprotein. Advances and Applications in 
Bioinformatics and Chemistry 10:11–28. DOI:10.2147/
aabc.s115859
De Paula SO et al. 2008. A DNA vaccine candidate expressing 
dengue-3 virus prM and E proteins elicits neutralizing 
antibodies and protects mice against lethal challenge. 
Archives of Virology 153:2215–2223. DOI:10.1007/
s00705-008-0250-3
Dimitrov I et al. 2014. AllergenFP: allergenicity prediction 
by descriptor fingerprints. Bioinformatics 30:846–851.
DOI:10.1093/bioinformatics/btt619
Dorigatti I et al. 2018. Using wolbachia for dengue control: 
Insights from modelling. Trends in Parasitology 
34:102–113. DOI:10.1016/j.pt.2017.11.002
Doytchinova IA, Flower DR. 2007. VaxiJen: a server for 
prediction of protective antigens, tumour antigens 
and subunit vaccines. BMC Bioinformatics 8:4. 
DOI:10.1186/1471-2105-8-4
Eisenberg D et al. 1997. VERIFY3D:assessment of protein 
models with three-dimensional profiles. Methods in 
Enzymology 277:396–404.
Emini EA et al. 1985. Induction of hepatitis a virus-
neutralizing antibody by a virus-specific synthetic 
peptide. Journal of virology 55:836–839. DOI:10.1128/
JVI.55.3.836-839.1985
Fahimi H et al. 2018. Dengue viruses and promising 
envelope protein domain III-based vaccines. Applied 
Microbiology and Biotechnology 102:2977–2996. DOI: 
10.1007/s00253-018-8822-y
Harapan H et al. 2019. Epidemiology of dengue hemorrhagic 
fever in Indonesia: analysis of five decades data from 
the National Disease Surveillance. BMC Research Notes 
12:350. DOI:10.1186/s13104-019-4379-9
Huang XJ et al. 2013. Cellular immunogenicity of a multi-
epitope peptide vaccine candidate based on hepatitis 
C virus NS5A, NS4B and core proteins in HHD-2 
mice. Journal of Virological Methods 189:47–52. DOI: 
10.1016/j.jviromet.2013.01.003
Jamil M, Anwar F. 2016. Properties, health benefits and 
medicinal Uses of Oryza sativa. European Journal of 
Biological Sciences 8:136–141. DOI:10.5829/idosi.
ejbs.2016.136.141
Karplus PA, Schulz GE. 1985. Prediction of chain flexibility 
in proteins. Naturwissenschaften 72:212–213. 
DOI:10.1007/bf01195768
Kelso JM et al. 1999. Anaphylaxis from yellow fever vaccine. 
Journal of Allergy and Clinical Immunology 103:698–
701. DOI:10.1016/S0091-6749(99)70245-9
Khetarpal N, Khanna I. 2016. Dengue fever:causes, 
complications, and vaccine strategies. Journal 
of Immunology Research 2016:6803098. 
DOI:10.1155/2016/6803098
Kolaskar AS, Tongaonkar PC. 1990. A semi-empirical method 
for prediction of antigenic determinants on protein 
antigens. FEBS Letters 276:172–174. DOI:10.1016/0014-
5793(90)80535-q
Kumar S et al. 2018. MEGA X:molecular evolutionary genetics 
analysis across computing platforms. Molecular 
Biology and Evolution 35:1547–1549. DOI:10.1093/
molbev/msy096
Lamiable A et al. 2016. PEP-FOLD3:faster de novo structure 
prediction for linear peptides in solution and in 
complex. Nucleic acids research 44:W449–W454. 
DOI:10.1093/nar/gkw329
Larsen JEP et al. 2006. Improved method for predicting linear 
B-cell epitopes. Immun Res 2:2. DOI:10.1186/1745-
7580-2-2
Larsen MV et al. 2007. Large-scale validation of methods 
for cytotoxic T-lymphocyte epitope prediction. BMC 
Bioinformatics 8:424. DOI:10.1186/1471-2105-8-424
Laskowski RA et al. 1993. PROCHECK:a program to check the 
stereochemical quality of protein structures. Journal 
of Applied Crystallography 26:283–291. DOI:10.1107/
s0021889892009944
Letunic I, Bork P. 2019. Interactive Tree Of Life (iTOL) v4: 
recent updates and new developments. Nucleic Acids 
Research 47:256–259. DOI:10.1093/nar/gkz239
Liu F et al. 2006. Peptide vaccination of mice immune to LCMV or 
vaccinia virus causes serious CD8+ T cell-mediated,  
TNF-dependent immunopathology. Journal of Clinical 
Investigation 116:465–475. DOI:10.1172/JCI25608
HAYATI J Biosci                                                                                                                                                                       99
Vol. 27 No. 2, April 2020
240                                                                          Adnan M et al.
Liu H et al. 2017. A novel polyepitope vaccine elicited HIV 
peptide specific CD4+ T cell responses in HLA-A2/
DRB1 transgenic mice. PLoS ONE 12:e0184207. DOI: 
10.1371/journal.pone.0184207
McNeil MM, DeStefano F. 2018. Vaccine-associated 
hypersensitivity. Journal of Allergy and Clinical 
Immunology 141:463–472. DOI:10.1016/j.
jaci.2017.12.971
Mustafa MS et al. 2015. Discovery of fifth serotype of dengue 
virus (denv-5):a new public health dilemma in dengue 
control. Medical Journal Armed Forces India 71: 67–70. 
DOI:10.1016/j.mjafi. 2014.09.011
Nadjib M et al. 2019. The economic burden of dengue in 
Indonesia. International Pest Control 61:90–91. 
DOI:10.1371/journal.pntd.0007038
Oyarzun P, Kobe. 2015. Computer-aided design of T-cell 
epitope-based vaccines: addressing population 
coverage. International Journal of Immunogenetics 
42:313–321. DOI:10.1111/iji.12214
Peters B, Sette A. 2005. Generating quantitative models 
describing the sequence specificity of biological 
processes with the stabilized matrix method. BMC 
Bioinformatics 6:132. DOI:10.1186/1471-2105- 6-132.
Prayitno A et al. 2017. Dengue seroprevalence and force of 
primary infection in a representative population of 
urban dwelling Indonesian children. PLoS Neglected 
Tropical Diseases 11:e0005621. DOI:10.1371/journal.
pntd.0005621
Quinan BR et al. 2016. A MVA construct expressing a secretable 
form of the Dengue virus 3 envelope p r o t e i n 
protects immunized mice from dengue-induced 
encephalitis. Vaccine 34: 6120–6122. DOI:10.1016/j.
vaccine.2016.10.058
Rodriguez-Tomé P et al. 1996. The european Bioinformatics 
Institute (EBI) databases. Nucleic Acids Research 24:6–
12. DOI:10.1093/nar/24.1.6
Rolf A et al. 2017. UniProt: The universal protein 
knowledgebase. Nuc Aci Res 45:158–169. DOI:10.1093/
nar/gkw1099
Sasmono RT et al. 2018. Dengue virus serotype distribution 
based on serological evidence in pediatric urban 
population in Indonesia. PLoS Neglected Tropical 
Diseases 12:e0006616. DOI:10.1371/ journal.
pntd.0006616
Sette A, Fikes J. 2003. Epitope-based vaccines: an update 
on epitope identification, vaccine design and 
delivery. Current Opinion in Immunology 15:461–470. 
DOI:10.1016/S0952-7915(03)00083-9
Shukla R et al. 2018. Pichia pastoris-expressed bivalent 
virus-like particulate vaccine induces domain III- 
focused bivalent neutralizing antibodies without 
antibody-dependent enhancement in vivo. Frontiers in 
Microbiology 8:2644. DOI:10.3389/fmicb.2017.02644
Sidney J. 2007. Development of an epitope conservancy 
analysis tool to facilitate the design of epitope-based 
diagnostics and vaccines. BMC Bioinformatics 8:361. 
DOI:10.1186/1471-2105-8-361
Soria-Guerra RE et al. 2015. An overview of bioinformatics 
tools for epitope prediction:implications on vaccine 
development. Journal of Biomedical Informatics 
53:405–414. DOI:10.1016/j.jbi.2014.11.003
Stanaway JD et al. 2016. The global burden of dengue:an 
analysis from the Global Burden of Disease Study 
2013. The Lancet Infectious Diseases 16:712–723. 
DOI:10.1016/S1473-3099(16)00026-8
Tahir Ul Qamar M et al. 2019. Epitope-based peptide vaccine 
design and target site depiction against Middle East 
Respiratory Syndrome Coronavirus:an immune-
informatics study. Journal of Translational Medicine 
17:362. DOI:10.1186/s12967-019-2116-8.
Tan PT et al. 2010. Conservation and diversity of influenza 
A H1N1 HLA-restricted T cell epitope candidates 
for epitope-based vaccines. PLoS ONE 5:e8754. DOI: 
10.1371/journal.pone.0008754
Tenzer S et al. 2005. Modeling the MHC class I pathway by 
combining predictions of proteasomal cleavage, TAP 
transport and MHC class I binding. Cellular and 
Molecular Life Sciences 62:1025–1037. DOI:10.1007/ 
s00018-005-4528-2
Tian Y et al. 2018. A review on T Cell epitopes identified using 
prediction and cell-mediated immune models for 
Mycobacterium tuberculosis and Bordetella pertussis. 
Frontiers in Immunology 9:2778. DOI:10.3389/
fimmu.2018.02778
Tripathi NK, Shrivastava A. 2018. Recent developments 
in recombinant protein-based dengue vaccines. 
Frontiers in immun-biology 9:1919. DOI:10.3389/
fimmu.2018.01919
Trott O, Olson AJ. 2009. Software news and update autodock 
vina:improving the speed and accuracy of docking with 
a new scoring function, efficient optimization, and 
multithreading. Journal of Computational Chemistry 
31:455–461. DOI:10.1002/jcc
Versiani AF et al. 2017. Multi-walled carbon nanotubes 
functionalized with recombinant Dengue 
virus 3 envelope proteins induce significant 
and specific immune responses in mice. Journal of 
Nanobiotechnology 15:26. DOI:10.1186/s12951-017-
0259-4
Xu D, Zhang Y. 2011. Improving the physical realism and 
structural accuracy of protein models by a two- step 
atomic-level energy minimization. Biophysical Journal 
101:2525–2534. DOI:10.1016/j.bpj.2011.10.024
